Liver transplant might cure liver metastases in a small subset of patients with CRC but identifying which patients could benefit most remains a challenge.
Their link with metastases, and thus with aggressive tumors, gives them an advantage over other biomarkers in the early identification of invasive tumors for therapeutic intervention.
Patients who underwent plasma ctDNA testing started therapy for advanced NSCLC earlier than those who underwent only tissue biopsy, but "plasma first does not mean plasma only," the authors say.